Tag: lymphoma cancer

REDLAMP 14: Does Routine Imaging After DLBCL Remission Improve Post-Treatment Survival?

Most patients with diffuse large B-cell lymphoma (DLBCL) patients achieve a long-term remission after first line treatment with combined immunotherapy and chemotherapy. Relapse can, however, sometimes occur after a period of DLBCL remission. Once a patient is in remission, the appropriateness of routine imaging (with CT or PET scans) for DLBCL patients is controversial and is believed by some to have limited value in detecting relapse. In a population based study published in the Journal of Clinical Oncology researchers from Denmark and Sweden compared the survival of different patients undergoing different types of routine imaging. In this video Dr. John Leonard explains the findings of this study in order to provide guidance in follow up monitoring strategies.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 212-746-2919.

Dr. John Leonard Discusses Emerging Treatment Options for Follicular Lymphoma

Recently, Lymphoma Program Director, Dr. John Leonard was interviewed by OncLive on the potential use of new therapies including lenalidomide, idelalisib, and ibrutinib in the treatment of follicular lymphoma. As Dr. Leonard noted,

“When patients relapse after initial therapy, the key factors in choosing a treatment include the time from first therapy, the time to reoccurrence, how sick they are, their age, and what they need in terms of symptom relief at that time…” 

The full interview can be read here.

A list of available clinical trials for follicular lymphoma available at Weill Cornell Medicine can be found in our clinical trials listing.

REDLAMP 13: How Are Outcomes Improving for Patients with Transformed Follicular Lymphoma?

The diagnosis for follicular lymphoma that has transformed into diffuse large B-cell lymphoma (DLBCL) has in the past been associated with a poor prognosis for patients. However, in a National LymphoCare Study recently published in Blood, researchers assessed the incidence, prognostic features, and outcomes associated with the transformation of follicular lymphoma in enrolled patients. In this video Dr. John Leonard discusses the findings of the study. Specifically reviewed are new data on outcomes, based on novel approaches and therapies for patients whose follicular lymphoma has transformed.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 212-746-2919.